Research Notes

Stay informed with the most recent market and company research insights.

A man sitting at a table with a glass of orange juice.

Research Notes

Detecting first Argus sales

Micro-X
3:27pm
February 28, 2024
Apart from the R&D incentive not being recognised as a receivable and the timing of project income, the 1H24 result was broadly in line with expectations. Argus sales remain the key focus and near-term catalyst. We have adjusted R&D forecasts resulting in a lower target price of A$0.25. Speculative Buy maintained.

FDA submission in sight; remains well-funded

EBR Systems
3:27pm
February 28, 2024
CY22 results were broadly in line, with opex up modestly and higher interest expense. The final Premarket Approval (PMA) module remains on track, with management confident in achieving FDA filing in 3QCY24 and approval in 1QCY25. We have made no changes to our estimates or A$1. target price. Speculative Buy recommendation maintained.

A compositional weaker result

NIB Holdings
3:27pm
February 27, 2024
NHF’s 1H24 underlying operating profit (A$144m) was +13% above consensus, but was a low quality beat driven by a Covid-19 provision release in the Australia Residents Health insurance business (ARHI). Excluding this release, the result was a bit softer than expected, particularly in the adjacent businesses (IIHI, NZ, Travel) which all came in below consensus. We lower NHF FY24F/FY25F NPAT forecasts by ~-3% on slightly softer earnings estimates in all key divisions. Our target price is set at A$8.00 (previously A$8.47). With upside to our valuation reduced, we move NHF back to our a Hold call.

Turning the ship

Cooper Energy
3:27pm
February 27, 2024
The real highlight in the 1H24 result was the progress reported at Orbost. With COE flagging continued results from debottlenecking would mitigate the need for a third absorber (which would save ~A$40m capex and deliver higher production). COE reported an impressive 1H24 result, finishing with an underlying NPAT of A$5.4m (vs Visible Alpha consensus/MorgansF -A$1.0/$4.7m). We maintain an Add rating on COE with an upgraded A$0.28ps Target Price.

Tempting to throw the baby out with the bath water

DGL Group
3:27pm
February 27, 2024
DGL delivered a weak 1H24, with NPAT declining 41% on the pcp, well below both our expectations and consensus. Whilst an element of the performance is cyclical, company guidance sees only modest improvement in 2H24, with the company forecasting FY24 NPAT to decline on the pcp. In discussing the result, management talked about investing for growth, expensing costs where possible, to allow the company to grow organically in years to come – something that comes at the cost of current P&L earnings. Whilst the narrative resonates, it isn’t lost on us that the predictability of DGL’s earnings continues to decline – DGL is likely to grow slower than we expected, with earnings more cyclical. It is on this basis that we apply a lower multiple to lower earnings, whilst retaining our Add recommendation on a lower target price of $0.77/sh.

Managing softer conditions well

Reece
3:27pm
February 27, 2024
REH’s 1H24 result was above expectations with earnings growth delivered in both ANZ and the US despite subdued macroeconomic conditions. Key positives: Group EBITDA margin increased 60bp to 11.6% with margins higher in both regions; ROCE rose 80bp to 16.1%; Balance sheet remains healthy with ND/EBITDA falling to 0.7x (FY23: 0.9x). Key negative: Demand remains subdued with management expecting a softening environment in ANZ in 2H24. We increase FY24-26F EBITDA by between 10-12%. Our target price increases to $22.10 (from $15.50) on the back of updates to earnings forecasts and a roll-forward of our model to FY25 forecasts. With a 12-month forecast TSR of -22%, we retain our Reduce rating. We continue to see REH as a good business with a strong brand and a long-term track record of investment for growth. However, trading on 41.9x FY25F PE and 1.0% yield, we think the stock is overvalued in the short term, especially relative to our growth forecast (3-year EPS CAGR of 5%).

Supermarkets performing well

Coles Group
3:27pm
February 27, 2024
COL’s 1H24 results was above expectations driven mainly by the core Supermarkets segment. Key positives: Supermarkets Own Brand sales increased 7.6% with eCom sales jumping 29.2%; Investments to reduce total loss saw an improvement in loss through 2Q24 with expectations for further benefits in 2H24; Supermarkets sales growth of 4.9% in early 2H24 was well above Woolworths’ (WOW) Australian Food growth of ~1.5%. Key negatives: Liquor earnings were below our forecast; Group EBIT margin fell 30bp to 4.8%. Following the better-than-expected 1H24 result and solid start to 2H24, we increase FY24-26F underlying EBIT by between 3-4%. This reflects upgrades to Supermarkets earnings forecasts, partially offset by downgrades to Liquor. Our target price rises by $18.70 (from $16.60) on the back of updates to earnings forecasts and a roll-forward of our model to FY25 forecasts. We maintain our Add rating with COL being our preference in the Consumer Staples sector.

Topline headwinds remain but margins improving

Articore
3:27pm
February 27, 2024
Articore Group’s (ATG) 1H24 marketplace revenue (MPR) was ~5% under consensus at ~A$260m (-13% on pcp on a constant currency basis) but broadly in line with consensus at GPAPA (~A$64m, +19% on pcp). Whilst management initiatives around improving the margin profile of the business appear on track, we note ATG expects the softer consumer environment to persist into the 2H and hence topline growth eludes at this juncture. We make several adjustments to our medium-term forecasts, predominantly related to: 1) the lower marketplace revenue environment; and 2) the narrowed FY24 margin guidance (details below). Our price target is altered marginally to A$0.70 from (A$0.71). Hold maintained.

1H in line- Working on a “step-change” in core ops

Healius
3:27pm
February 27, 2024
1H results were pre-released so in line, with underlying Op income falling by double-digits and margins compressing. Pathology was the main drag, negatively impacted by cycling out of covid-19 testing, combined with low volumes and cost inflation, while Lumus Imaging was “ahead of target” on strength in the hospital and community segments, and Agilex showed “positive signs” on increasing new contracts. While management is accelerating Pathology restructuring to better match volumes with costs, aiming for a “step-change” by FY26/27, uncertainty around the impact of numerous initiatives make forecasting challenging and unreliable. We lower our FY24-26 estimates, with our target price decreasing to A$1.32. Hold

Execution on point

SiteMinder
3:27pm
February 27, 2024
1H24 underlying EBITDA/NPAT was below MorgansF and consensus. Subscribers, revenue, and cashflow were pre-released at SDR’s 2Q24 update. The highlight for us was SDR continuing to demonstrate ongoing improvement in its profitability and unit economics whilst maintaining solid growth momentum. Management said the 2H24 has started well and reiterated FY24 guidance for positive underlying EBITDA and FCF in 2H24. SDR continues to target medium-term organic revenue growth of 30%. We continue to think SDR offers an attractive long-term growth opportunity underpinned by its global underpenetrated TAM and opportunity to better monetise its A$70bn of Gross Booking Value (currently captures ~0.2%). ADD maintained.

News & Insights

Michael Knox, Chief Economist looks at what might have happened in January 2026 if the cuts in corporate tax rates in Trumps first term were not renewed and extended in the One Big Beautiful Bill

In recent weeks, a number of media commentators have criticized Donald Trump's " One big Beautiful Bill " on the basis of a statement by the Congressional Budget Office that under existing legislation the bill adds $US 3.4 trillion to the US Budget deficit. They tend not to mention that this is because the existing law assumes that all the tax cuts made in 2017 by the first Trump Administration expire at the end of this year.

Let’s us look at what might have happened in January 2026 if the cuts in US corporate tax rates in Trumps first term were not renewed and extended in the One Big Beautiful Bill.

Back in 2016 before the first Trump administration came to office in his first term, the US corporate tax rate was then 35%. In 2017 the Tax Cut and Jobs Act reduced the corporate tax rate to 21%. Because this bill was passed as a "Reconciliation Bill “, This meant it required only a simple majority of Senate votes to pass. This tax rate of 21% was due to expire in January 2026.

The One Big Beautiful Bill has made the expiring tax cuts permanent; this bill was signed into law on 4 July 2025. Now of course the same legislation also made a large number of individual tax cuts in the original 2017 bill permanent.

What would have happened if the bill had not passed. Let us construct what economists call a "Counterfactual"

Let’s just restrict ourselves to the case of what have happened in 2026 if the US corporate tax had risen to the prior rate of 35%.

This is an increase in the corporate tax rate of 14%. This increase would generate a sudden fall in US corporate after-tax earnings in January 2026 of 14%. What effect would that have on the level of the S&P 500?

The Price /Earnings Ratio of the S&P500 in July 2025 was 26.1.

Still the ten-year average Price/ Earnings Ratio for the S&P500 is only 18.99. Let’s say 19 times.

Should earnings per share have suddenly fallen by 14%, then the S&P 500 might have fallen by 14% multiplied by the short-term Price/ Earnings ratio.

This means a likely fall in the S&P500 of 37%.

As the market recovered to long term Price Earnings ratio of 19 this fall might then have ben be reduced to 27%.

Put simply, had the One Big, beautiful Bill not been passed, then in 2026 the US stock market might suddenly have fallen by 37% before then recovering to a fall of 27% .

The devastating effect on the US and indeed World economy might plausibly have caused a major recession.

On 9 June Kevin Hassert the Director of the National Economic Council said in a CBS interview with Margaret Brennan that if the bill did not pass US GDP would fall by 4% and 6-7 million Americans would lose their jobs.

The Passage of the One Big Beautiful Bill on 4 July thus avoided One Big Ugly Disaster.

Read more
On 7 July the AFR published a list of 37 Economists who had answered a poll on when the RBA would next cut rates. 32 of them thought that the RBA would cut on 8 July. Only 5 of them did not believe the RBA would cut, Michael Knox being one of them.

On 7 July the AFR published a list of 37 Economists who had answered a poll on when the RBA would next cut rates. 32 of them thought that the RBA would cut on 8 July. Only 5 of them did not believe the RBA would cut on 8 July. I was one of them. The RBA did not cut.

So today I will talk about how I came to that decision. First, lets look at our model of official interest rates. Back in January 2015 I went to a presentation in San Franciso by Stan Fishcer . Stan was a celebrated economist who at that time was Ben Bernanke's deputy at the Federal Reserve. Stan gave a talk about how the Fed thought about interest rates.

Stan presented a model of R*. This is the real short rate of the Fed Funds Rate at which monetary policy is at equilibrium. Unemployment was shown as a most important variable. So was inflationary expectations.

This then logically lead to a model where the nominal level of the Fed funds rate was driven by Inflation, Inflationary expectations and unemployment. Unemployment was important because of its effect on future inflation. The lower the level of unemployment the higher the level of future inflation and the higher the level of the Fed funds rate. I tried the model and it worked. It worked not just for the Fed funds rate. It also worked in Australia for Australian cash rate.

Recently though I have found that while the model has continued to work to work for the Fed funds rate It has been not quite as good in modelling that Australian Cash Rate. I found the answer to this in a model of Australian inflation published by the RBA. The model showed Australian Inflation was not just caused by low unemployment, It was also caused by high import price rises. Import price inflation was more important in Australia because imports were a higher level of Australian GDP than was the case in the US.

This was important in Australia than in the US because Australian import price inflation was close to zero for the 2 years up to the end of 2024. Import prices rose sharply in the first quarter of 2025. What would happen in the second quarter of 2025 and how would it effect inflation I could not tell. The only thing I could do is wait for the Q2 inflation numbers to come out for Australia.

I thought that for this reason and other reasons the RBA would also wait for the Q2 inflation numbers to come out. There were other reasons as well. The Quarterly CPI was a more reliable measure of the CPI and was a better measure of services inflation than the monthly CPI. The result was that RBA did not move and voiced a preference for quarterly measure of inflation over monthly version.

Lets look again at R* or the real level of the Cash rate for Australia .When we look at the average real Cash rate since January 2000 we find an average number of 0.85%. At an inflation target of 2.5 % this suggests this suggest an equilibrium Cash rate of 3.35%

Model of the Australian Cash Rate.
Model of the Australian Cash Rate


What will happen next? We think that the after the RBA meeting of 11 and 12 August the RBA will cut the Cash rate to 3.6%

We think that after the RBA meeting of 8 and 9 December the RBA will cut the Cash rate to 3.35%

Unless Quarterly inflation falls below 2.5% , the Cash rate will remain at 3.35% .

Read more
Investment Watch is a quarterly publication for insights in equity and economic strategy. Recent months have been marked by sharp swings in market sentiment, driven by shifting global trade dynamics, geopolitical tensions, and policy uncertainty.

Investment Watch is a quarterly publication produced by Morgans that delves into key insights for equity and economic strategy.

This publication covers

Economics - 'The challenge of Australian productivity' and 'Iran, from the Suez blockade to the 12 day war'
Asset Allocation
- 'Prioritise portfolio resilience amidst the prevailing uncertainty'
Equity Strategy
- 'Rethinking sector preferences and portfolio balance'
Fixed Interest
- 'Market volatility analysis: Low beta investment opportunities'
Banks
- 'Outperformance driving the broader market index'
Industrials
- 'New opportunities will arise'
Resources and Energy
- 'Getting paid to wait in the majors'
Technology
- 'Buy the dips'
Consumer discretionary
- 'Support remains in place'
Telco
- 'A cautious eye on competitive intensity'
Travel
- 'Demand trends still solid'
Property
- 'An improving Cycle'

Recent months have been marked by sharp swings in market sentiment, driven by shifting global trade dynamics, geopolitical tensions, and policy uncertainty. The rapid pace of US policy announcements, coupled with reversals, has made it difficult for investors to form strong convictions or accurately assess the impact on growth and earnings. While trade tariffs are still a concern, recent progress in US bilateral negotiations and signs of greater policy stability have reduced immediate headline risks.

We expect that more stable policies, potential tax cuts, and continued innovation - particularly in AI - will support a gradual pickup in investment activity. In this environment, we recommend prioritising portfolio resilience. This means maintaining diversification, focusing on quality, and being prepared to adjust exposures as new risks or opportunities emerge. This quarter, we update our outlook for interest rates and also explore the implications of the conflict in the Middle East on portfolios. As usual, we provide an outlook for the key sectors of the Australian market and where we see the best tactical opportunities.


Morgans clients receive exclusive insights such as access to our latest Investment Watch publication. Contact us today to begin your journey with Morgans.

      
Contact us
      
      
Find an adviser
      
Read more